Compare CNTN & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTN | SWKH |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | 12 | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.3M | 198.4M |
| IPO Year | 2022 | N/A |
| Metric | CNTN | SWKH |
|---|---|---|
| Price | $3.58 | $16.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 441.5K | 104.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.89 | $13.86 |
| 52 Week High | $5.27 | $17.90 |
| Indicator | CNTN | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 32.19 |
| Support Level | $3.01 | $14.69 |
| Resistance Level | $3.82 | $17.08 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 69.47 | 12.06 |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.